Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

Clinical significance of chitotriosidase in outpatients with advanced heart failure

Sara Cetin Sanlialp, Gokay Nar, Hande Senol
DOI: 10.1136/jim-2020-001595 Published 4 March 2021
Sara Cetin Sanlialp
1 The Department of Cardiology, Servergazi State Hospital, Denizli, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara Cetin Sanlialp
Gokay Nar
2 The Department of Cardiology, Pamukkale University Medical Faculty, Denizli, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hande Senol
3 The Department of Biostatistics, Pamukkale University Medical Faculty, Denizli, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    The comparison of plasma CHIT levels in patients with CHF and controls. CHF, chronic heart failure; CHIT, chitotriosidase.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    The comparison of plasma CHIT levels according to etiology of heart failure. CHIT, chitotriosidase; HF, heart failure.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    The correlation between CHIT and NT-proBNP in heart failure according to underlying etiology. CHIT, chitotriosidase; HF, heart failure; NT-proBNP, N-terminal pro brain natriuretic peptide.

Tables

  • Figures
  • Table 1

    Baseline characteristics, laboratory data and medications

    Patients (n=36)Controls (n=27)P value
    Baseline characteristics
     Mean age (years)63.17±10.1861.33±8.730.455
     Males, n (%)18 (50)12 (44)0.662
     Body mass index (kg/m2)28.38±5.1328.91±4.970.682
     Hypertension, n (%)17 (47)9 (33)0.268
     Diabetes mellitus, n (%)–14 (39)0.0001
     Smoking, n (%)3 (8)5 (19)0.272
     Systolic blood pressure (mm Hg)119.89±13.44117.37±13.570.466
     Diastolic blood pressure (mm Hg)76.72±10.5673.48±8.730.200
     Heart rate (beats/min)74.58±13.2470.78±13.290.177
     Atrial fibrillation, n (%)10 (28)–0.003
     LVEDD (mm)60.86±5.5646.19±3.78<0.001
     LVESD (mm)49.11±6.4029.04±3.03<0.001
     LVEF (%)27.27±5.2360.17±3.21<0.001
    Laboratory findings
     FPG (mg/dL)115.33±28.6495.44±10.570.002
     Creatinine (mg/dL)0.96±0.160.72±0.10<0.001
     GFR (mL/min/m2)75.15±13.7789.04±13.69<0.001
     Sodium (mEq/L)139.22±3.46140.74±1.810.028
     T-chol (mg/dL)188.78±46.34197.11±39.710.456
     TG (mg/dL)163.64±77.40117.41±64.470.002
     LDL-C (mg/dL)110.17±31.27118.56±30.650.292
     HDL-C (mg/dL)40.61±7.2754.85±13.43<0.001
     Hemoglobin (g/L)137.00±13.00142.50±13.300.08
     WBC (cells/μL)9.07±2.076.6±1.46<0.001
     Albumin (g/dL)4.27±0.264.56±0.25<0.001
     NT-proBNP (pg/mL)595.31±428.1178.13±30.47<0.001
     Chitotriosidase (ng/mL)931.25±461.39232.79±61.28<0.001
    Medication, n (%)
     ACE inhibitor/ARB27 (75)8 (30)<0.001
     Beta-blockers32 (89)2 (7)<0.001
     Statins13 (36)1 (4)0.002
     Loop diüretics23 (64)–<0.001
     Aldosterone antagonist19 (53)–<0.001
     Antiplatelet agents34 (94)5 (19)<0.001
     Digoxine9 (25)–<0.001
    • ACE, angiotensin-converting enzyme; ; ARB, angiotensin receptor blocker; FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; T-chol, total cholesterol; TG, triglycerides; WBC, white blood cells.

  • Table 2

    Characteristics of study patients according to the etiology

    IHF (n=20)NIHF (n=16)P value
    Baseline characteristics
     Mean age (years)63.45±10.4962.81±10.110.855
     Males, n (%)10 (50)8 (50)1.000
     Body mass index (kg/m2)29.19±6.1327.38±3.450.272
     Hypertension, n (%)10 (50)7 (44)0.709
     Diabetes mellitus, n (%)9 (45)5 (31)0.400
     Smoking, n (%)2 (10)1 (6)1.000
     Systolic blood pressure (mm Hg)120.65±16.78118.94±7.920.69
     Diastolic blood pressure (mm Hg)75.20±12.2578.63±7.970.404
     Heart rate (beats/min)73.15±12.0376.38±14.810.476
     Atrial fibrillation, n (%)5 (25)5 (31)0.722
     LVEDD (mm)61.90±6.4659.56±4.020.386
     LVESD (mm)50.45±7.3947.44±4.600.290
     LVEF (%)25.57±5.1429.39±4.670.027
     NYHA I–II, n (%)6 (30)10 (63)0.05
     NYHA III–IV, n (%)14 (70)6 (37)0.05
    Laboratory findings
     FPG (mg/dL)121.90±29.01107.13±26.810.062
     Creatinine (mg/dL)1.02±0.190.89±0.070.012
     GFR (mL/min/m2) 70.24±14.6881.29±9.840.011
     Sodium (mEq/L)139±3.29139.5±3.740.44
     T-chol (mg/dL)177.35±43.16203.06±47.540.099
     TG (mg/dL)167.40±90.53158.94±59.640.888
     LDL-C (mg/dL)108.35±32.05112.44±31.140.703
     HDL-C (mg/dL)38.45±7.8143.31±5.650.02
     Hemoglobin (g/L)139.40±13.10133.90±12.600.215
     WBC (cells/μL)9.70±2.078.29±1.840.049
     Albumin (g/dL)4.24±0.274.30±0.260.508
     NT-proBNP (pg/mL)792.87±461.26348.36±202.610.001
     Chitotriosidase (ng/mL)1139.28±495.22671.22±237.210.002
    Medication, n (%)
     ACE inhibitor/ARB13 (65)14 (88)0.245
     Beta-blockers18 (90)14 (88)0.813
     Statins12 (60)1 (6)0.001
     Loop diüretics15 (75)8 (50)0.121
     Aldosterone antagonist10 (50)9 (56)0.709
     Antiplatelet agents18 (90)16 (100)0.492
     Digoxine5 (25)4 (25)1.000
    • ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IHF, ischemic heart failure; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NIHF, non-ischemic heart failure; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; NYHA, New York Heart Association; T-chol, total cholesterol; TG, triglycerides; WBC, white blood cells.

  • Table 3

    The correlation analysis of chitotriosidase in patients with heart failure

    VariablesRP value
    Mean age0.5150.001
    Body mass index−0.1460.397
    Systolic blood pressure−0.0820.635
    Diastolic blood pressure−0.1860.277
    Heart rate0.1640.340
    LVEDD0.0080.962
    LVESD0.0760.660
    LVEF−0.4910.002
    FPG0.1830.284
    Creatinine0.3450.04
    GFR−0.693<0.001
    Sodium−0.2670.116
    T-chol−0.0570.743
    TG0.2260.229
    LDL-C0.1010.557
    HDL-C−0.0680.692
    Hemoglobin−0.2410.157
    WBC0.680<0.001
    Albumin−0.4220.01
    NT-proBNP0.969<0.001
    • FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; T-chol, total cholesterol; TG, triglycerides; WBC, white blood cells.

PreviousNext
Back to top
Vol 69 Issue 3 Table of Contents
Journal of Investigative Medicine: 69 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical significance of chitotriosidase in outpatients with advanced heart failure
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Clinical significance of chitotriosidase in outpatients with advanced heart failure
Sara Cetin Sanlialp, Gokay Nar, Hande Senol
Journal of Investigative Medicine Mar 2021, 69 (3) 736-741; DOI: 10.1136/jim-2020-001595

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Clinical significance of chitotriosidase in outpatients with advanced heart failure
Sara Cetin Sanlialp, Gokay Nar, Hande Senol
Journal of Investigative Medicine Mar 2021, 69 (3) 736-741; DOI: 10.1136/jim-2020-001595
Download PDF

Share
Clinical significance of chitotriosidase in outpatients with advanced heart failure
Sara Cetin Sanlialp, Gokay Nar, Hande Senol
Journal of Investigative Medicine Mar 2021, 69 (3) 736-741; DOI: 10.1136/jim-2020-001595
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Abstract
    • Introduction
    • Materials
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Altered degree centrality in patients with non-neuropsychiatric systemic lupus erythematosus: a resting-state fMRI study
  • Organochlorine pesticides, oxidative stress biomarkers, and leukemia: a case-control study
  • Temporal trends and disparities in gastroenterology care use before, during, and after COVID-19 lockdown
Show more Original research

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2023 American Federation for Medical Research